Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
RadNet subsidiary receives FDA clearance for AI mammography triage software » 06:06
04/19/21
04/19
06:06
04/19/21
06:06
RDNT

RadNet

$22.21 /

+0.07 (+0.32%)

RadNet subsidiary…

RadNet subsidiary DeepHealth, a developer of artificial intelligence for mammography interpretation, has received FDA clearance for its mammography triage software Saige-Q. Saige-Q is a screening worklist prioritization tool that enables radiologists to manage their mammography cases with the use of artificial intelligence.

ShowHide Related Items >><<
RDNT RadNet
$22.21 /

+0.07 (+0.32%)

RDNT RadNet
$22.21 /

+0.07 (+0.32%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
RDNT RadNet
$22.21 /

+0.07 (+0.32%)

Over a month ago
Earnings
RadNet sees FY21 revenue $1.25B-$1.3B, consensus $1.22B » 06:05
03/08/21
03/08
06:05
03/08/21
06:05
RDNT

RadNet

$18.90 /

+0.57 (+3.11%)

Sees FY21 adjusted EBITDA…

Sees FY21 adjusted EBITDA $180M-$190M.

ShowHide Related Items >><<
RDNT RadNet
$18.90 /

+0.57 (+3.11%)

RDNT RadNet
$18.90 /

+0.57 (+3.11%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
RDNT RadNet
$18.90 /

+0.57 (+3.11%)

Earnings
RadNet reports Q4 adjusted EPS 20c, consensus 15c » 06:04
03/08/21
03/08
06:04
03/08/21
06:04
RDNT

RadNet

$18.90 /

+0.57 (+3.11%)

Reports Q4 revenue…

Reports Q4 revenue $308.5M, consensus $300.63M.

ShowHide Related Items >><<
RDNT RadNet
$18.90 /

+0.57 (+3.11%)

RDNT RadNet
$18.90 /

+0.57 (+3.11%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
RDNT RadNet
$18.90 /

+0.57 (+3.11%)

Over a quarter ago
Conference/Events
Jefferies to hold a virtual conference » 04:55
11/19/20
11/19
04:55
11/19/20
04:55
MRNA

Moderna

$88.90 /

-4.225 (-4.54%)

, IMGN

ImmunoGen

$5.75 /

-0.035 (-0.61%)

, ESPR

Esperion

$29.18 /

-0.95 (-3.15%)

, CRL

Charles River

$234.11 /

-2.205 (-0.93%)

, AXGN

AxoGen

$15.16 /

-0.05 (-0.33%)

, INMD

InMode

$42.75 /

+0.16 (+0.38%)

, PRTA

Prothena

$12.10 /

-0.24 (-1.94%)

, SYNH

Syneos Health

$63.21 /

-0.24 (-0.38%)

, RDNT

RadNet

$18.19 /

-0.75 (-3.96%)

, OPNT

Opiant Pharmaceuticals

$7.95 /

+0.2 (+2.58%)

, FGEN

FibroGen

$41.56 /

-2.58 (-5.85%)

, MGLN

Magellan Health

$82.25 /

-2.47 (-2.92%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.66 /

-0.53 (-3.27%)

, IVA

Inventiva

$14.00 /

+ (+0.00%)

, ITOS

iTeos Therapeutics

$25.09 /

+1.14 (+4.76%)

, CLBS

Caladrius

$1.44 /

-0.055 (-3.68%)

, ALNA

Allena Pharmaceuticals

$1.37 /

-0.07 (-4.86%)

, SEEL

Seelos Therapeutics

$0.78 /

-0.0296 (-3.65%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$10.82 /

-0.23 (-2.08%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$29.18 /

-0.95 (-3.15%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$234.11 /

-2.205 (-0.93%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.75 /

+0.16 (+0.38%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.10 /

-0.24 (-1.94%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.19 /

-0.75 (-3.96%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+ (+0.00%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

10/01/20 B. Riley
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/20
11/18
04:55
11/18/20
04:55
MRNA

Moderna

$93.12 /

-4.88 (-4.98%)

, IMGN

ImmunoGen

$5.78 /

+0.03 (+0.52%)

, ESPR

Esperion

$30.13 /

+0.02 (+0.07%)

, CRL

Charles River

$236.30 /

-1.56 (-0.66%)

, AXGN

AxoGen

$15.29 /

+0.18 (+1.19%)

, INMD

InMode

$42.61 /

+0.8 (+1.91%)

, PRTA

Prothena

$12.34 /

-0.03 (-0.24%)

, SYNH

Syneos Health

$63.45 /

-0.37 (-0.58%)

, RDNT

RadNet

$18.94 /

-0.05 (-0.26%)

, OPNT

Opiant Pharmaceuticals

$7.78 /

-0.02 (-0.26%)

, FGEN

FibroGen

$44.14 /

+1.12 (+2.60%)

, MGLN

Magellan Health

$84.72 /

-0.64 (-0.75%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$16.19 /

+0.5 (+3.19%)

, IVA

Inventiva

$14.00 /

+0.175 (+1.27%)

, ITOS

iTeos Therapeutics

$23.95 /

-0.08 (-0.33%)

, CLBS

Caladrius

$1.50 /

-0.005 (-0.33%)

, ALNA

Allena Pharmaceuticals

$1.43 /

-0.15 (-9.49%)

, SEEL

Seelos Therapeutics

$0.81 /

-0.0119 (-1.45%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.04 /

+0.03 (+0.27%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.13 /

+0.02 (+0.07%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$236.30 /

-1.56 (-0.66%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.61 /

+0.8 (+1.91%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.34 /

-0.03 (-0.24%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.94 /

-0.05 (-0.26%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+0.175 (+1.27%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

10/01/20 B. Riley
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

Conference/Events
Jefferies to hold a virtual conference » 08:54
11/17/20
11/17
08:54
11/17/20
08:54
MRNA

Moderna

$97.95 /

+8.65 (+9.69%)

, IMGN

ImmunoGen

$5.75 /

-0.1 (-1.71%)

, ESPR

Esperion

$30.11 /

+1.45 (+5.06%)

, CRL

Charles River

$237.94 /

-0.75 (-0.31%)

, AXGN

AxoGen

$15.09 /

+0.445 (+3.04%)

, INMD

InMode

$41.88 /

-0.01 (-0.02%)

, PRTA

Prothena

$12.37 /

+0.07 (+0.57%)

, SYNH

Syneos Health

$63.82 /

+0.48 (+0.76%)

, RDNT

RadNet

$18.99 /

+0.43 (+2.32%)

, OPNT

Opiant Pharmaceuticals

$7.83 /

+0.045 (+0.58%)

, FGEN

FibroGen

$43.03 /

+0.79 (+1.87%)

, MGLN

Magellan Health

$85.23 /

+0.11 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.69 /

+0.28 (+1.82%)

, IVA

Inventiva

$14.00 /

-0.005 (-0.04%)

, ITOS

iTeos Therapeutics

$24.03 /

+0.36 (+1.52%)

, CLBS

Caladrius

$1.50 /

-0.01 (-0.66%)

, ALNA

Allena Pharmaceuticals

$1.58 /

+0.07 (+4.64%)

, SEEL

Seelos Therapeutics

$0.82 /

-0.0299 (-3.52%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.01 /

-0.05 (-0.45%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
11/17/20 BMO Capital
Moderna downgraded to Market Perform from Outperform at BMO Capital
IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.11 /

+1.45 (+5.06%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$237.94 /

-0.75 (-0.31%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$41.88 /

-0.01 (-0.02%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.37 /

+0.07 (+0.57%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.99 /

+0.43 (+2.32%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

-0.005 (-0.04%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

10/01/20 B. Riley
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

Earnings
RadNet reports Q3 adjusted EPS 15c, consensus (8c) » 06:03
11/09/20
11/09
06:03
11/09/20
06:03
RDNT

RadNet

$16.77 /

-0.05 (-0.30%)

Reports Q3 revenue…

Reports Q3 revenue $291.8M, consensus $259.89M.

ShowHide Related Items >><<
RDNT RadNet
$16.77 /

-0.05 (-0.30%)

RDNT RadNet
$16.77 /

-0.05 (-0.30%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
RDNT RadNet
$16.77 /

-0.05 (-0.30%)

Hot Stocks
RadNet forms JV with CommonSpirit Health » 06:11
10/27/20
10/27
06:11
10/27/20
06:11
RDNT

RadNet

$15.85 /

-0.06 (-0.38%)

RadNet reported it has…

RadNet reported it has expanded operations into Arizona by establishing its third outpatient radiology joint venture with CommonSpirit Health and completing the acquisition of AZ Tech MRI & Radiology, an eight location multimodality radiology practice. The Phoenix, Arizona venture expands the existing commitment of RadNet and Dignity Health, which is part of CommonSpirit Health, to provide high-quality imaging services to targeted medical communities and patient populations. With this new joint venture, to be known as Arizona Diagnostic Radiology Group, RadNet has established an operating platform in the Phoenix metropolitan area, a rapidly growing market and home to almost five million people. Under the joint venture, RadNet and Dignity Health will develop a network of multi-modality outpatient imaging centers, expanding the geographic coverage of the acquired locations through a combination of new site development and acquisition of existing radiology providers. This network of centers will provide high quality, accessible imaging services in and around the communities served by the Dignity Health hospitals and medical group practices in the Phoenix area. The imaging locations provide multimodality radiology including MRI, CT, Mammography, PET/CT, Ultrasound, X-ray, and Nuclear Medicine.

ShowHide Related Items >><<
RDNT RadNet
$15.85 /

-0.06 (-0.38%)

RDNT RadNet
$15.85 /

-0.06 (-0.38%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
RDNT RadNet
$15.85 /

-0.06 (-0.38%)

Earnings
RadNet executes partnership agreement with Adventist Health » 06:06
10/20/20
10/20
06:06
10/20/20
06:06
RDNT

RadNet

$16.29 /

-0.45 (-2.69%)

RadNet reported it has…

RadNet reported it has executed a partnership agreement with Adventist Health to create an outpatient imaging joint venture in Simi Valley, California to initially include three outpatient facilities. Under the new joint venture, RadNet will contribute two of its Simi Valley imaging Centers, Alamo Advanced Imaging and Simi Valley Advanced Imaging, and Adventist Health will contribute its Aspen Imaging Center. The facilities will together operate MRI, CT, PET/CT, Ultrasound and X-ray modalities. In addition, RadNet will assume the operational management of Adventist Health's Nancy Reagan Breast Center, which will perform mammography, breast ultrasound, imaging-guided biopsies and related women's health services.

ShowHide Related Items >><<
RDNT RadNet
$16.29 /

-0.45 (-2.69%)

RDNT RadNet
$16.29 /

-0.45 (-2.69%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
RDNT RadNet
$16.29 /

-0.45 (-2.69%)

Recommendations
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus » 10:47
09/03/20
09/03
10:47
09/03/20
10:47
AKU

Akumin

$0.00 /

+ (+0.00%)

, RDNT

RadNet

$15.00 /

-0.195 (-1.28%)

After Akumin's (AKU)…

After Akumin's (AKU) shares began trading on the Nasdaq, Clarus analyst Noel Atkinson noted that this means that the two largest U.S. outpatient imaging sector operators - RadNet (RDNT) and Akumin - will be listed on a major U.S. exchange, which he views as a positive for the sector. If Akumin shares performs well post-listing, he would not be surprised to also see some of larger privately-held competitors - like SimonMed, CDI, or Touchstone - go public through an IPO or a SPAC, Atkinson added. The analyst, who thinks greater awareness of Akumin and its recent performance should increase with U.S. investors and potentially drive a re-rating of the stock, has a Buy rating and $6 price target on Akumin shares.

ShowHide Related Items >><<
RDNT RadNet
$15.00 /

-0.195 (-1.28%)

AKU Akumin
$0.00 /

+ (+0.00%)

RDNT RadNet
$15.00 /

-0.195 (-1.28%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.